In PALOMA-2, with a 10-month improvement of PFS as the first-line treatment for advanced HR-positive, HER2-negative breast cancer, when combined with letrozole, palbociclib represents one of the best steps forward in the treatment of luminal breast cancer9. The gene discussed is ERBB2; the disease is breast cancer.